Comparison
DSIP vs. GHK-Cu
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Cosmetic
CAS no.
62568-57-4
49557-75-7
Molecular weight
848.81 g/mol
340.4 g/mol
Half-life
0.1 h
no data
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluGHKMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
GHK-Cu
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. In skin-cell models and skin biopsies an influence on collagen synthesis, antioxidant markers, gene-expression profiles and wound-healing processes has been described. In topical use in cosmetic studies, changes in various skin parameters have been reported.
Evidence base
Highest evidence
Human trial
Human trial
Studies
4
3
of which in humans
1
1
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
1
2